On this page
Quick answer
Trials show that particular treatments can reduce weight and, in specific groups, cardiovascular events. These are population averages, not guarantees of individual weight loss or equal benefits across all medicines.
Educational information for adults. This is not a prescription or an individual medical assessment. Longevity Online is a wellbeing plan: it does not include medicines or obesity treatment. GLP‑1 use requires a medical indication, prescription and healthcare follow-up.
Medical terms, explained
Hover, use keyboard focus or tap an underlined word to see its meaning.
Read all definitions
- GLP-1
- Glucagon-like peptide-1: a gut hormone involved in insulin release after eating and appetite regulation. Source
- GIP
- Glucose-dependent insulinotropic polypeptide: a gut hormone that helps release insulin in response to food. Source
- BMI
- Body mass index: weight in kilograms divided by height in metres squared. An indicative measure, not a measure of body composition. Source
- Waist/height
- Waist circumference divided by height in the same units. Helps assess central adiposity alongside BMI; it is not a diagnosis. Source
What is the evidence for weight loss?
STEP 1 compared semaglutide with placebo for 68 weeks in adults with obesity or overweight with a weight-related condition, without diabetes. Both groups received a lifestyle intervention.
Mean weight change was −14.9% with semaglutide and −2.4% with placebo. These are percentages of starting weight, not kilograms, and do not predict an individual's result. The trial did not test all medicines in the class.
Are there benefits beyond weight?
SELECT enrolled adults aged 45 or over with established cardiovascular disease, overweight or obesity and no diabetes. It compared semaglutide with placebo for cardiovascular death, non-fatal heart attack or non-fatal stroke.
The primary event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months. The hazard ratio was 0.80: the relative reduction based on that analysis was 20%. The difference between observed proportions was 1.5 percentage points. These measures are not interchangeable.
The findings do not establish the same effect in people without established cardiovascular disease or with every medicine. They do not demonstrate rejuvenation or a reduction in biological age.
How should benefits and limits be weighed?
Healthcare professionals consider goals, related conditions, tolerance, other medicines and continuity of care. A favourable average result must be read alongside adverse effects and the trial population.
This summary is educational. STEP 1 and SELECT are not a direct comparison between semaglutide and tirzepatide or a purchasing recommendation.
BMI and waist-to-height ratio
An indicative tool for adults aged at least 18 who are not pregnant. Enter height and weight; waist measurement is optional. All length measurements must be in centimetres (cm).
Calculated on this device. These measurements are not saved or sent anywhere.
These results are neither a diagnosis nor a probability of disease. No number alone indicates treatment with GLP-1 or any other medicine; decisions require clinical assessment.
How to read these numbers
This tool excludes people under 18 and pregnant people. BMI does not distinguish fat from muscle: high muscle mass can affect its interpretation. For adults over 65, function, nutritional status and other circumstances must be considered. Clinical context and ethnic background also matter: no universal BMI classification is applied here to everyone.
NICE NG246 uses waist-to-height ratio alongside BMI in adults with BMI <35. Its bands are a central adiposity reference, not an assessment of overall health.
Technical validation limits: height 100–250 cm, weight 20–400 kg and waist 30–250 cm. These are not clinical cut-offs and do not define what is healthy; consult a professional if your measurements fall outside them.
Source: NICE NG246 · recommendations 1.9.5, 1.9.8, 1.9.14 and 1.9.15 (Opens in a new tab)
2025 guideline · checked on 10 November 2026.
Frequently asked questions
Does everyone lose 14.9% of their weight?
No. It was the mean change with semaglutide at 68 weeks in STEP 1's specific population. Individual responses vary.
Does a 20% relative reduction mean 20 percentage points?
No. In SELECT a hazard ratio of 0.80 expresses a 20% relative reduction in the time-to-event analysis. Observed proportions were 6.5% and 8.0%, a difference of 1.5 percentage points.
Do these medicines rejuvenate people?
STEP 1 and SELECT did not measure rejuvenation or a reduction in biological age. Their results concern weight and specific clinical events.
Original sources
Source publication date or date regulatory information was checked.
- Wilding et al. · STEP 1 · New England Journal of Medicine(Opens in a new tab)
2021-02-10
https://pubmed.ncbi.nlm.nih.gov/33567185/
- Lincoff et al. · SELECT · New England Journal of Medicine(Opens in a new tab)
2023-11-11
https://pubmed.ncbi.nlm.nih.gov/37952131/
- WHO · Global guideline on GLP-1 medicines and obesity(Opens in a new tab)
2025-12-01
https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity